Our platform leverages chemical synthesis for efficient mucosal vaccination.
Unlike mRNA vaccines, our synthetic STxB induces robust CD8+ T cell responses and mucosal IgA and IgG, crucial for preventing viral spread.
This innovation is advancing in preclinical stages, with ongoing COVID-19 and Head & Neck carcinoma model studies demonstrating promising in vitro and in vivo proof of concept.
